Baird Capital Partners Asia Portfolio Company Adds Eisenach To The Board,
Saccente As VP Of Sales
CHICAGO, October 30, 2008
Baird Capital Partners Asia (BCPA), the China-focused investment group of Baird Private Equity, announced today that its portfolio company Frontage Laboratories Inc. (Frontage) has added Mark Eisenach to its Board of Directors and has hired Vito Saccente as Vice President of Sales. Frontage is a leading high quality provider of bioanalytical, pre-clinical and drug development services to the pharmaceutical industry with facilities in Pennsylvania (Malvern and Exton) and in China (Shanghai). Earlier this year, Frontage acquired Advanced Biomedical Research, Inc. (ABR), a full-service, Phase I-IV global CRO headquartered in Princeton, N.J. with affiliated offices in the United Kingdom, France and Germany.
“We are very excited to have Mark joining our Board and Vito leading our sales efforts,” said Dr. Song Li, Chairman & CEO of Frontage. “Having Mark’s strategic insight and deep CRO experience at the Board level will help us continue to grow. Vito has established a successful track record in the healthcare sector of building sales teams that focus on clients’ needs. Both Mark and Vito will be tremendous assets to our company.”
Frontage provides research services to facilitate pharmaceutical discovery, development and commercialization, assisting its clients with resolving complex product development issues and advancing drug candidates through preclinical and clinical development stages to commercialization. The company’s clients include four of the top ten largest pharmaceutical companies in the world.
“We are pleased to welcome Mark and Vito to Frontage,” said Brett Tucker, BCPA Partner and a member of the Frontage board of directors. “Helping identify and attract talented individuals like Mark and Vito is just one of the many ways in which Baird Capital Partners Asia is helping Song and Frontage build their business.”
Biography – Mark Eisenach
Eisenach has more than 20 years of corporate development, strategy, and executive management experience, primarily in the healthcare and high technology industries. He is currently founder and Managing Director of Ridgeview Partners LLC, a Princeton, N.J.-based corporate advisory firm, and previously served as CEO of pharmaceutical services company Acurian Inc. Prior to that, he held a variety of senior executive positions at Covance Inc., one of the world's largest and most comprehensive drug development services companies. In these roles, he led Covance's worldwide business strategy, mergers and acquisitions, business partnerships and global marketing efforts, serving on the company's Global Leadership Council. Earlier in his career, he spent eight years at the Boston Consulting Group and was a tax economist at Price Waterhouse. He received his AB from Harvard College and his MBA from Harvard Business School.
Biography – Vito Saccente
Frontage hired Saccente to build the Company’s global sales force and establish customer focused policies and procedures. Saccente’s 20-year sales career in the healthcare industry includes previous sales leadership positions at Tandem Labs, Aptuit, and AAI Pharma. In each of those roles, Saccente built, led and motivated national sales teams that successfully met or exceeded the companies’ sales targets. Saccente received his bachelor’s degree from Monmouth College.
About Frontage Laboratories, Inc.
Frontage Laboratories, Inc., which recently acquired Advanced Biomedical Research, Inc., is a rapidly expanding pharmaceutical R&D services company with offices in the greater Philadelphia, PA area, Shanghai, P.R. China and Princeton, N.J., and affiliates in the United Kingdom, France and Germany. Frontage recognizes the importance of developing cost-effective and efficacious pharmaceutical treatments; as a result, the company is focused on collaborating with its clients to discover and develop new cures and healthcare advances. Frontage is called on by leading pharmaceutical companies to solve complex development issues and advance their pharmaceutical products through the FDA approval process. Each employee plays an important part in the success of the organization.
About Baird Capital Partners Asia
Baird Capital Partners Asia, the China-focused investment group of Baird Private Equity, provides growth equity capital to smaller, high-potential companies with substantial operations and growth opportunities in China. Baird Capital Partners Asia leverages its in-depth sector knowledge, experienced investment team and extensive operating resources to drive value in its portfolio companies. Baird Capital Partners Asia has representative offices in Hong Kong, Beijing, and Shanghai, and invests in three industry sectors: manufactured products, business services and healthcare. For more information, please visit www.bairdcapitalpartnersasia.com.
About Baird Private Equity
Baird Private Equity, the global private equity group affiliated with Robert W. Baird & Co. (Baird), makes venture capital, growth equity and buyout investments in smaller, high potential companies in the United States through Baird Venture Partners and Baird Capital Partners, in China through Baird Capital Partners Asia, and in Europe through Baird Capital Partners Europe and Granville Baird, an affiliated fund manager that invests in Germany. Baird Private Equity has a global team of 80 professionals in nine offices across the United States, Europe and Asia, including approximately 20 operating professionals in Asia. Baird Private Equity and its affiliates have raised and managed approximately $2.4 billion in capital and invested in over 225 companies since the 1980s. For more information, please visit www.bairdprivateequity.com.
For additional information contact:
Vice President, Sales
Frontage Laboratories, Inc.
Chairman & CEO
Frontage Laboratories, Inc.
Baird Capital Partners Asia